Fake Drugs in Africa: Risks & Science
- The deaths of approximately 70 children in the Gambia between July and October 2023 are being attributed to contaminated cough syrup.
- The tragedy highlights the critical need for stringent quality control in pharmaceutical manufacturing and distribution.
- Increased scrutiny of pharmaceutical supply chains and enhanced regulatory oversight are expected in the wake of this incident.
The tragic deaths of 70 Gambian children from tainted cough syrup highlight a severe crisis in medicine regulation. This incident, caused by a cough syrup found to contain deadly levels of ethylene glycol, underscores the dangers of substandard pharmaceuticals. Effective medicine regulation is paramount to public health. The crisis requires more oversight in the pharmaceutical supply chains and robust quality control standards to prevent similar tragedies.News Directory 3 is committed to informing you on such critical events as they unfold.Discover what’s next in pharmaceutical oversight.
Gambia Cough Syrup Deaths Spur Calls for Medicine Regulation
Updated June 6, 2025
The deaths of approximately 70 children in the Gambia between July and October 2023 are being attributed to contaminated cough syrup. The medicine regulation crisis unfolded after the children, all under age 5, consumed a cough syrup that contained hazardous levels of ethylene glycol and diethylene glycol. both chemicals are toxic to humans.
The tragedy highlights the critical need for stringent quality control in pharmaceutical manufacturing and distribution. Substandard and falsified medicines, often deliberately misrepresenting their composition or source, pose a significant threat to public health. This medicine regulation failure demands coordinated leadership and thorough data collection to prevent future occurrences.
What’s next
Increased scrutiny of pharmaceutical supply chains and enhanced regulatory oversight are expected in the wake of this incident. International health organizations are likely to collaborate with Gambian authorities to implement stricter quality control measures and prevent the distribution of substandard medications.